Tenax Therapeutics (TENX) has provided an update.
Tenax Therapeutics, Inc.’s stockholders approved a significant expansion of their stock incentive plan during the 2024 Annual Meeting, paving the way for more shares to be available for incentives. Additionally, the company modified its Chief Medical Officer’s employment agreement to a part-time schedule with a corresponding salary adjustment. Key election results and approvals also included the re-election of board members and the ratification of an independent auditor for the upcoming year, with future plans to address executive compensation at the 2025 meeting.
See more data about TENX stock on TipRanks’ Stock Analysis page.
